Vacthera

Vacthera is a Vienna-based biotechnology company specializing in the development of innovative vaccines using its proprietary deltaNS1 influenza virus platform. This technology utilizes a replication-deficient influenza virus that lacks the non-structural protein 1 (NS1), allowing for high levels of interferon induction and enhanced immune responses. The company's pipeline primarily targets respiratory diseases, including seasonal influenza and COVID-19, with a focus on intranasal administration to provide mucosal immunity. Vacthera aims to provide more effective and safer vaccine alternatives compared to traditional methods.